BioCryst stock rises after $264 million sale of European ORLADEYO business

Published 27/06/2025, 13:20
© Reuters.

Investing.com -- BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) stock jumped 4.2% Friday after the company announced it will sell its European ORLADEYO business to Neopharmed Gentili for up to $264 million.

The deal includes an upfront payment of $250 million upon closing, which is expected by early October, and up to $14 million in future milestones tied to sales in Central and Eastern Europe. BioCryst plans to use the proceeds to completely retire its remaining $249 million term debt from Pharmakon, eliminating approximately $70 million in future interest payments.

As a result of this transaction, BioCryst has significantly improved its financial outlook, now expecting to end 2027 with approximately $700 million in cash and no term debt—a $400 million increase from its previous net cash guidance.

"This transaction is consistent with our strategy of making ORLADEYO available to patients in Europe through the team we built, and it now provides the capital to retire our remaining term debt, leaving us with a significantly higher margin business," said Jon Stonehouse, president and CEO of BioCryst.

The deal includes the transfer of BioCryst’s European organization to Neopharmed Gentili, which will maintain commercial continuity for ORLADEYO while generating at least $50 million in expected annual operating expense savings for BioCryst.

Neopharmed Gentili will assume responsibility for all royalties related to European sales, though European ORLADEYO revenues will still count toward BioCryst’s global royalty tier calculations and the cap on the OMERS royalty.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.